Skip to main content

Unable to load price data. Sorry.


Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX.DL)

CAPS Rating: No stars

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:PGNX.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

1760mill (< 20)
Submitted September 15, 2006

Drug for opioid-induced constipation has had very good trial results. FDA submission next year. Also discovered receptor HIV uses to enter cells, a potential blockbuster drug target, but still pretty far off.

zzlangerhans (99.94)
Submitted July 15, 2015

Progenics has acquired a cult following of sorts but I'm at a loss to understand the appeal. The main thing the company seems to have going is a recently-submitted NDA of Relistor subcutaneous injection for opioid-induced constipation in non-cancer… More


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about PGNX.DL.

No one has written a Pitch for PGNX.DL stock yet. Tell us why you think PGNX.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in PGNX.DL.

No players have picked PGNX.DL yet. Tell us why you think PGNX.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PGNX.DL.